NEW YORK (GenomeWeb News) - Eli Lilly & Co. said today that it will provide free access to its drug discovery technology to potential collaborators who want to evaluate the therapeutic potential of their compounds.

Under the new program, called the Phenotypic Drug Discovery Initiative, or PD2, Lilly said it will provide free, confidential access to its drug discovery assays via a secure web portal in a move intended to provide "a more convenient point of entry for global external researchers into Lilly's drug discovery and development process."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.